SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-047460
Filing Date
2023-02-24
Accepted
2023-02-24 07:00:56
Documents
12
Period of Report
2023-02-23
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Document Format Files

Seq Description Document Type Size
1 8-K d414055d8k.htm   iXBRL 8-K 27591
  Complete submission text file 0001193125-23-047460.txt   153418

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20230223.xsd EX-101.SCH 2836
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20230223_lab.xml EX-101.LAB 18758
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20230223_pre.xml EX-101.PRE 11701
6 EXTRACTED XBRL INSTANCE DOCUMENT d414055d8k_htm.xml XML 3484
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 23662311
SIC: 2834 Pharmaceutical Preparations